Oncology News | pharmaphorum

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

As Blenrep returns, GSK adds another ADC to cancer pipeline

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

News

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

MSD, Eisai abandon combination trial in liver cancer

As Blenrep returns, GSK adds another ADC to cancer pipeline

Bayer's prostate cancer drug Nubeqa cleared for NHS use

GSK's Blenrep's back in US, but with a narrower label

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Takeda builds in cancer with monster $11.4bn Innovent deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks